ZRE Stock Chart & Stats
€11.00
-€0.04(-0.36%)
At close: 4:00 PM EDT
€11.00
-€0.04(-0.36%)
Day’s Range― - ―
52-Week Range€4.31 - €17.59
Previous CloseN/A
Volume2.00
Average Volume (3M)1.76K
Market Cap
€862.00M
Enterprise Value€604.15M
Total Cash (Recent Filing)€89.80M
Total Debt (Recent Filing)€265.68M
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Mar 18, 2027EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding54,000,000
10 Day Avg. Volume1,469
30 Day Avg. Volume1,765
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.75
Price to Sales (P/S)0.27
P/FCF Ratio-3.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.31Price Target Upside30.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.79
Revenue Forecast (FY)€1.36B
Bulls Say, Bears Say
Bulls Say
Prescription Growth And RetentionStrong prescription growth and improving retention indicate rising adoption of DocMorris’s digital pharmacy proposition. Larger, more loyal Rx cohorts can support repeat purchasing, customer lifetime value, and a more durable revenue base as e-prescription usage expands.
Digital Healthcare Platform ExpansionRapid Digital Services and TeleClinic growth strengthens DocMorris’s position beyond online product fulfillment. Increasing treatment volumes and platform usage can deepen customer engagement, support cross-selling, and improve the scalability of higher-margin healthcare services.
Operating Efficiency And Breakeven ProgressThe combination of recurring AI-led savings, lower marketing expense, and improving margins provides a credible path toward better operating leverage. If execution continues, these initiatives can reduce the structural cost base and support the targeted EBITDA and cash-flow breakeven milestones.
Bears Say
Persistent UnprofitabilitySustained losses and negative operating profitability show that revenue growth has not yet translated into durable earnings. Continued losses can constrain internal investment capacity, weaken returns on equity, and leave the business dependent on successful execution of its cost and growth plans.
Cash Burn And Higher Net DebtNegative operating cash flow combined with rising net debt reduces financial flexibility while the company remains on a multi-year path to cash-flow breakeven. If improvement is delayed, ongoing funding needs could limit investment options and increase balance-sheet pressure.
Regulatory And Co-payment PressureChanges to pharmacy remuneration, statutory discounts, and patient co-payments could pressure pricing, demand, or reimbursement economics in Germany. Greater price sensitivity may make customer acquisition and retention harder and could limit the profitability benefits of Rx expansion.
DocMorris News
ZRE FAQ
What was DocMorris AG’s price range in the past 12 months?
DocMorris AG lowest stock price was €4.31 and its highest was €17.59 in the past 12 months.
What is DocMorris AG’s market cap?
DocMorris AG’s market cap is €862.00M.
When is DocMorris AG’s upcoming earnings report date?
DocMorris AG’s upcoming earnings report date is Mar 18, 2027 which is in 146 days.
How were DocMorris AG’s earnings last quarter?
DocMorris AG released its earnings results on Aug 19, 2026. The company reported -€1.185 earnings per share for the quarter.
Is DocMorris AG overvalued?
According to Wall Street analysts DocMorris AG’s price is currently Undervalued.
Does DocMorris AG pay dividends?
DocMorris AG does not currently pay dividends.
What is DocMorris AG’s EPS estimate?
DocMorris AG’s EPS estimate is -0.62.
How many shares outstanding does DocMorris AG have?
DocMorris AG has 54,000,000 shares outstanding.
What happened to DocMorris AG’s price movement after its last earnings report?
DocMorris AG reported an EPS of -€1.185 in its last earnings report. Following the earnings report the stock price went up 3.627%.
Which hedge fund is a major shareholder of DocMorris AG?
Currently, no hedge funds are holding shares in DE:ZRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DocMorris AG
DocMorris AG is a key player in the pharmaceutical sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and personal care lines, dietary supplements, pain relief remedies, and emergency first aid supplies. Furthermore, it offers specialized medication management support. In addition to its significant digital footprint, DocMorris AG also operates traditional brick-and-mortar pharmacy locations. Its commercial activities extend across Switzerland and into various international territories, serving medical practitioners, other online pharmaceutical distributors, and individual consumers directly. Notable brands within its portfolio include Zur Rose, PromoFarma, TeleClinic, and DocMorris. Established in 1993 and based in Frauenfeld, Switzerland, the company adopted its current name, DocMorris AG, in May 2023, having previously been known as Zur Rose Group AG.
ZRE Stock 12 Month Forecast
Average Price Target
€14.31
▲(30.07% Upside)